Literature DB >> 18286380

A case-control study of the protective benefit of cervical screening against invasive cervical cancer in NSW women.

Baohui Yang1, Stephen Morrell, Yeqin Zuo, David Roder, Elizabeth Tracey, Paul Jelfs.   

Abstract

OBJECTIVE: To examine the effects of different Pap screening patterns in preventing invasive cervical cancer among women in New South Wales, Australia.
METHODS: A total of 877 women aged 20-69 years diagnosed with invasive cervical cancer during 2000-2003 were matched with 2,614 controls by month and year of birth. Screening behavior patterns in 4 years preceding the time of cancer diagnosis in the cases were classified into none (no Pap test in the 4 years), 'irregular' (1 of the 4 years with Pap test(s)), and 'regular' (2 or more of the 4 years with a Pap test), and compared with those in the matched non-cases over the same period. Conditional logistic regression modeling was used to estimate the relative risk, approximated by the odds ratio, of invasive cervical cancer for regular and irregular cervical screening compared with no screening in the previous 4 years, before and after controlling for potential confounders including the first recorded Pap test result in the preceding 6-year reference period.
RESULTS: Compared with no screening, irregular Pap screening in the 4 years preceding the cancer diagnosis is estimated to reduce the risk of invasive cervical cancer by about 85% (RR = 0.15, 95% CI: 0.120-0.19); regular Pap screening reduces the risk by about 96% (RR = 0.04, 95% CI: 0.03-0.05). After adjusting for the index Pap test result, the relative risks for invasive cervical cancer were 0.19 (95% CI: 0.13-0.27) for irregular screening and 0.07 (95% CI: 0.04-0.10) for regular Pap screening.
CONCLUSIONS: Regular and irregular Pap tests among women aged 20-69 years were highly effective in preventing invasive cancer. At-risk women with no Pap test history should be encouraged to undergo a Pap test every 2 years, but any Pap screening over a 4-year period remains highly protective against future invasive cervical cancer.

Entities:  

Mesh:

Year:  2008        PMID: 18286380     DOI: 10.1007/s10552-008-9118-9

Source DB:  PubMed          Journal:  Cancer Causes Control        ISSN: 0957-5243            Impact factor:   2.506


  7 in total

1.  Recommendations on screening for cervical cancer.

Authors:  James Dickinson; Eva Tsakonas; Sarah Conner Gorber; Gabriela Lewin; Elizabeth Shaw; Harminder Singh; Michel Joffres; Richard Birtwhistle; Marcello Tonelli; Verna Mai; Meg McLachlin
Journal:  CMAJ       Date:  2013-01-07       Impact factor: 8.262

2.  Impact of endoscopic surveillance on mortality from Barrett's esophagus-associated esophageal adenocarcinomas.

Authors:  Douglas A Corley; Kunal Mehtani; Charles Quesenberry; Wei Zhao; Jolanda de Boer; Noel S Weiss
Journal:  Gastroenterology       Date:  2013-05-11       Impact factor: 22.682

3.  Exposure Definition in Case-Control Studies of Cervical Cancer Screening: A Systematic Literature Review.

Authors:  Alejandra Castanon; Aruna Kamineni; K Miriam Elfström; Anita W W Lim; Peter Sasieni
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2021-09-14       Impact factor: 4.254

4.  Effectiveness of cervical screening with age: population based case-control study of prospectively recorded data.

Authors:  Peter Sasieni; Alejandra Castanon; Jack Cuzick
Journal:  BMJ       Date:  2009-07-28

Review 5.  Screening for cervical cancer: a systematic review and meta-analysis.

Authors:  Leslea Peirson; Donna Fitzpatrick-Lewis; Donna Ciliska; Rachel Warren
Journal:  Syst Rev       Date:  2013-05-24

6.  Improvement of Outcomes for Women With HIV Infection and Cervical Cancer.

Authors:  Linda R Mileshkin; Alison E Freimund
Journal:  J Clin Oncol       Date:  2016-11-01       Impact factor: 44.544

7.  Impact of screening on cervical cancer incidence: A population-based case-control study in the United States.

Authors:  Rebecca Landy; Peter D Sasieni; Christopher Mathews; Charles L Wiggins; Michael Robertson; Yolanda J McDonald; Daniel W Goldberg; Isabel C Scarinci; Jack Cuzick; Cosette M Wheeler
Journal:  Int J Cancer       Date:  2019-12-31       Impact factor: 7.316

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.